[{"arm_notes": "", "treatment_id": null, "treatment_name": "Cohort 1: 220 Healthy subjects; of 55 to 85 years of age; with and close contact (cohabit) with a person or a cluster of persons with newly SARS-CoV-2 infection; and currently SARS-CoV-2 negative by PCR and antibody testing to confirm that they have not had SARS-CoV-2Cohort 2: 54 asymptomatic and/or symptomatic patients of 18 to 85 years of age with mild/moderate COVID-19 pneumonia confirmed by RT-PCR within the last 24 hours prior to the enrolment in the studyThe groups will be randomized and blindly assigned to receive orally either the 3 g LCT supplement or placebo. Subjects from Cohort 2 will receive LCT in addition to Standard of Care (SOC) therapy or placebo in addition to SOC therapy;G07.203.300.456", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 720, "treatment_name": "L-carnitine", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": 720, "treatment_name": "L-carnitine", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]